ES2187659T3 - Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina. - Google Patents

Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.

Info

Publication number
ES2187659T3
ES2187659T3 ES96921467T ES96921467T ES2187659T3 ES 2187659 T3 ES2187659 T3 ES 2187659T3 ES 96921467 T ES96921467 T ES 96921467T ES 96921467 T ES96921467 T ES 96921467T ES 2187659 T3 ES2187659 T3 ES 2187659T3
Authority
ES
Spain
Prior art keywords
amilina
agonists
type
treatment
mellitus diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96921467T
Other languages
English (en)
Spanish (es)
Inventor
Orville G Kolterman
Robert G Thompson
John F Mullane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2187659T3 publication Critical patent/ES2187659T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES96921467T 1995-06-07 1996-06-07 Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina. Expired - Lifetime ES2187659T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/483,188 US6143718A (en) 1995-06-07 1995-06-07 Treatment of Type II diabetes mellutis with amylin agonists

Publications (1)

Publication Number Publication Date
ES2187659T3 true ES2187659T3 (es) 2003-06-16

Family

ID=23919034

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96921467T Expired - Lifetime ES2187659T3 (es) 1995-06-07 1996-06-07 Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.

Country Status (19)

Country Link
US (2) US6143718A (enExample)
EP (1) EP0772451B1 (enExample)
JP (1) JP4009319B2 (enExample)
AT (1) ATE228849T1 (enExample)
AU (1) AU721489B2 (enExample)
BG (1) BG101230A (enExample)
CA (1) CA2196999C (enExample)
CZ (1) CZ289043B6 (enExample)
DE (1) DE69625157T2 (enExample)
DK (1) DK0772451T3 (enExample)
ES (1) ES2187659T3 (enExample)
HU (1) HUP9700368A3 (enExample)
IN (1) IN181672B (enExample)
NO (1) NO970519L (enExample)
PT (1) PT772451E (enExample)
RU (1) RU2166958C2 (enExample)
SK (1) SK18697A3 (enExample)
WO (1) WO1996040220A1 (enExample)
ZA (1) ZA964838B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
CZ69596A3 (en) * 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
EP1044015B1 (en) * 1998-01-09 2008-10-08 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides with insulin
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
ATE412421T1 (de) * 2002-01-08 2008-11-15 Amylin Pharmaceuticals Inc Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie
AU2003259131A1 (en) * 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
BRPI0411165A (pt) * 2003-05-14 2006-07-11 Emisphere Tech Inc composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
EP1644027B1 (en) * 2003-07-16 2014-04-09 Evotec International GmbH Use of pleiotrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
ATE471340T1 (de) * 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
CA2556923A1 (en) * 2004-02-20 2005-09-09 Rinat Neuroscience Corp. Methods of treating obesity or diabetes using nt-4/5
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
CN101193626A (zh) * 2005-03-11 2008-06-04 益德威士医药股份有限公司 奥曲肽的受控释放制剂
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
CN101400367A (zh) * 2006-02-02 2009-04-01 瑞纳神经科学公司 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
WO2008078179A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
UA97707C2 (ru) * 2007-11-14 2012-03-12 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и заболеваний, расстройств, связанных с ожирением
CA2729139C (en) 2008-06-25 2016-07-26 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
EP2303226B1 (en) * 2008-06-25 2016-03-23 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
CA2755068C (en) * 2009-03-12 2018-11-06 Keybioscience Ag Treatment of diabetes and metabolic syndrome
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
WO2016034604A1 (en) * 2014-09-04 2016-03-10 Novo Nordisk A/S Novel amylin and calcitonin receptor agonist
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
CA2100745C (en) * 1991-11-19 2007-07-31 Laura S. L. Gaeta Amylin agonist peptides and uses therefor
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
CZ69596A3 (en) * 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides

Also Published As

Publication number Publication date
CA2196999C (en) 2012-09-04
JP4009319B2 (ja) 2007-11-14
ZA964838B (en) 1997-02-24
EP0772451A1 (en) 1997-05-14
AU6268596A (en) 1996-12-30
NO970519D0 (no) 1997-02-05
EP0772451A4 (en) 1998-09-30
CZ33797A3 (en) 1997-07-16
CZ289043B6 (cs) 2001-10-17
HUP9700368A3 (en) 2001-03-28
BG101230A (en) 1997-10-31
AU721489B2 (en) 2000-07-06
DK0772451T3 (da) 2003-01-06
DE69625157T2 (de) 2003-04-17
JPH10503785A (ja) 1998-04-07
ATE228849T1 (de) 2002-12-15
US6417164B1 (en) 2002-07-09
US6143718A (en) 2000-11-07
CA2196999A1 (en) 1996-12-19
DE69625157D1 (de) 2003-01-16
HU9700368D0 (en) 1997-04-28
PT772451E (pt) 2003-04-30
HUP9700368A2 (hu) 1998-06-29
EP0772451B1 (en) 2002-12-04
NO970519L (no) 1997-04-07
WO1996040220A1 (en) 1996-12-19
IN181672B (enExample) 1998-08-29
RU2166958C2 (ru) 2001-05-20
SK18697A3 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
EP1159961A3 (en) Treatment of tumors with compounds having RxR retinoid receptor agonist activity
AU1718400A (en) Method for treating pain
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
PT777483E (pt) Metodos e meio para administrar farmacos
FR12C0052I2 (fr) Utilisation de dapoxetine, un inhibiteur selectif de recaptage de serotonine a action rapide, pour traiter un dysfonctionnement sexuel
ES2074565T3 (es) Empleo de melatonina para tratar el sindrome pre-menstrual.
EA200101089A1 (ru) Новый способ лечения
ES2068705T3 (es) Tratamiento de la enfermedad neoplastica con interleuquina-10.
ES2131122T3 (es) Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BR9810444A (pt) Tratamento de diabete com rosiglitazona e insulina
EA199800866A1 (ru) Способ снятия боли
ES2055314T3 (es) Tratamiento de disfuncion leucocitaria con gm-csf.
ES2136724T3 (es) Emulsion liofilizada, que contiene una sustancia activa.
BR9810186A (pt) Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade
BR9810292A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase
EA200000039A1 (ru) Лечение диабета тиазолидиндионом и сульфонилмочевиной
MX9206135A (es) Metodos
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
EP0904094A4 (en) TREATMENT OF BONE DISEASES WITH ADRENOMEDULLIN
AU551108B2 (en) Analgesic potentiation of zomepirac with butorphanol
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.